AcelRx Pharmaceuticals Inc $7.25

down -0.08


16/9/2014 05:03 PM  |  NASDAQ : ACRX  
Industries : Health Services / Medical Appliances & Equipment
Get Trend Analysis Icon Get ACRX Trend Analysis - it has underperformed the S&P 500 by 50%

Partner Headlines

  1. AcelRx falls on FDA rejection

    IBD
  2. AcelRx Pharma Plunges After FDA Rejects Device

    IBD
  3. Morning Market Losers

    Benzinga
  4. AcelRX Selling Off Sharply On FDA Reexamination

    Benzinga
  5. Benzinga's Top Downgrades

    Benzinga
  6. Benzinga's Top #PreMarket Losers

    Benzinga
  7. Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. US Stock Futures Down In Pre-Market Trade

    Benzinga
  10. Top Funds Like Facebook And Health Care Stocks

    IBD
  11. AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO

    Benzinga
  12. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data

    Benzinga
  13. AcelRx Announces Zalviso NDA Accepted for Filing by FDA

    Benzinga
  14. AcelRx Pharma Issues NDA for Zalviso, Submission Required Payment of $1.95M ...

    Benzinga
  15. UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals on Numerous Potential ...

    Benzinga
  16. AcelRx Pharma Announces Exercise of Option to Buy Additional Shares

    Benzinga
  17. Benzinga's Top Pre-Market Gainers

    Benzinga
  18. AcelRx Pharmaceuticals Prices 12.5M Share Offering at $3.31/Share

    Benzinga
  19. A Peek Into The Market Before The Trading Starts

    Benzinga
  20. FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority ...

    Benzinga
  21. AcelRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab ...

    Benzinga
  22. AcelRx Pharmaceuticals Doses the First Subjects in ARX-04 Phase 2 Study

    Benzinga
  23. AcelRx Receives Notice of Eligibility for Centralized Review from European ...

    Benzinga
  24. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume ...

    Benzinga
  25. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral ...

    Benzinga
  26. AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the ...

    Benzinga
  27. Morning Market Losers

    Benzinga
Trading Center